What this is
- How it works
- How it works isn't classified yet
- Tested for
- Sensorineural Hearing Loss, Bilateral
- Main trialPhase 3
- “Part A of this trial evaluated the safety and tolerability of a single surgical administration procedure in one or both ear(s) with one of two dose levels of AAVAnc80-hOTOF (LY888891) and evaluated the Akouos Delivery Device, together with the Precision Delivery Mechanism (as applicable), to safely achieve the intended product performance. Part B of the trial is an open-label, global expansion phase to confirm the efficacy and safety of one dose level of AAVAnc80-hOTOF administered in one or both ear(s). Part B will also evaluate the Intracochlear Delivery System (IDS), which consists of the…”In the company’s words, NCT05821959 on ClinicalTrials.gov
Other drugs for Sensorineural Hearing Loss, Bilateral
- N-Acetylcysteine AmideNacuity Pharmaceuticals, Inc. · Phase 3
- SENS-501Sensorion · Phase 1/2
- DX243Dendrogenix · Phase 2
- SKY-GJB2Skylark Bio Inc. · Phase 1/2
- UltevursenLaboratoires Thea · Phase 2
- Otic neural progenitorsRinri Therapeutics · Phase 1/2
Coming up1
- Oct 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Oct 2028 | Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026